~~UNITED STATES SECURITIES AND EXCHANGE COMMISSION~~0001604924--12-312022Q22022-06-30false00016049242022-01-012022-06-300001604924fwp:ForwardPharmaGmbhMemberifrs-full:DiscontinuedOperationsMemberfwp:ForwardPharmaGmbhMember2022-06-300001604924fwp:MajorEquityAwardsTransactionsMember2022-11-092022-11-090001604924ifrs-full:IssuedCapitalMember2022-01-012022-06-300001604924ifrs-full:IssuedCapitalMember2021-01-012021-06-300001604924ifrs-full:RetainedEarningsMember2022-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-06-300001604924ifrs-full:IssuedCapitalMember2022-06-300001604924ifrs-full:RetainedEarningsMember2021-12-310001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-12-310001604924ifrs-full:IssuedCapitalMember2021-12-310001604924ifrs-full:RetainedEarningsMember2021-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-06-300001604924ifrs-full:IssuedCapitalMember2021-06-300001604924ifrs-full:RetainedEarningsMember2020-12-310001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2020-12-310001604924ifrs-full:IssuedCapitalMember2020-12-310001604924country:DEfwp:ForwardPharmaGmbhMemberifrs-full:UnusedTaxCreditsMember2022-06-300001604924ifrs-full:RetainedEarningsMember2022-01-012022-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-01-012022-06-300001604924ifrs-full:RetainedEarningsMember2021-01-012021-06-300001604924ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-01-012021-06-300001604924fwp:ForwardPharmaGmbhMember2022-06-3000016049242021-06-3000016049242020-12-310001604924ifrs-full:DiscontinuedOperationsMemberfwp:ForwardPharmaGmbhMember2022-06-300001604924country:DE2022-01-012022-06-300001604924country:DEfwp:ForwardPharmaGmbhMemberifrs-full:UnusedTaxCreditsMember2022-07-012022-07-010001604924country:DEfwp:ForwardPharmaGmbhMember2022-07-012022-07-010001604924country:DEfwp:ForwardPharmaGmbhMemberifrs-full:UnusedTaxCreditsMember2022-06-302022-06-300001604924country:DEfwp:ForwardPharmaGmbhMember2021-05-212021-05-210001604924country:DEfwp:ForwardPharmaGmbhMember2021-05-202021-05-200001604924ifrs-full:TopOfRangeMemberfwp:ServiceAgreementMembersrt:ScenarioForecastMember2029-01-012029-01-010001604924ifrs-full:BottomOfRangeMemberfwp:ServiceAgreementMember2021-01-012021-01-010001604924ifrs-full:ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMemberfwp:ForwardPharmaGmbhMember2019-04-012022-07-310001604924country:DK2022-01-012022-06-300001604924ifrs-full:AggregatedIndividuallyImmaterialBusinessCombinationsMember2017-02-012017-02-280001604924ifrs-full:DiscontinuedOperationsMemberfwp:ForwardPharmaGmbhMember2022-06-302022-06-300001604924ifrs-full:ChangesInTaxRatesOrTaxLawsEnactedOrAnnouncedMemberfwp:ForwardPharmaGmbhMember2022-07-310001604924fwp:ForwardPharmaGmbhMember2022-06-300001604924ifrs-full:CountryOfDomicileMember2022-01-012022-06-3000016049242021-01-012021-06-3000016049242022-06-3000016049242021-12-31iso4217:USDxbrli:sharesiso4217:EURxbrli:purefwp:subsidiaryiso4217:USDxbrli:sharesiso4217:DKK

~~Washington, D.C. 20549~~

FORM 6-K

~~REPORT OF FOREIGN PRIVATE ISSUER~~

~~Pursuant~~SECURITIES toAND ~~Rule 13a-16~~EXCHANGE ~~or 15d-16 of the~~COMMISSION

~~Securities~~Washington, ~~Exchange~~D.C. ~~Act of 1934~~20549

~~September~~Report ~~12,~~of ~~2022~~Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

November 9, 2022

Commission File Number: 001-36686

Forward Pharma A/S

~~Østergade 24A, 1st Floor~~

Østergade 24A, 1 1100 Copenhagen K, Denmark

~~Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.~~

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F ☒or Form 40-F ☐.

~~Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐~~

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐


	Form 20-F ☒	Form 40-F ☐

~~Item 1. EBA Petition Request~~

AsIndicate ~~previously~~by ~~disclosed,~~check ~~Forward~~mark ~~Pharma~~if ~~A/S (~~the ~~“Company”)~~ registrant is ~~involved~~submitting ~~in an opposition proceeding (~~the ~~“Opposition~~Form ~~Proceeding”)~~6-K ~~regarding~~in ~~EP2801355~~paper ~~(the~~as ~~“EP’355~~permitted ~~patent”) with~~by ~~several~~Regulation ~~opponents~~S-T ~~including~~Rule ~~a subsidiary of Biogen Inc. On January 27, 2022, the Company submitted a petition for review~~ 101(~~the “Petition”~~b) ~~to the Enlarged Board of Appeal~~ (~~the “EBA”~~1) ~~of the European Patent Office (the “EPO”)~~. The Petition requested that the EBA review the decision of the Technical Board of Appeal (the “TBA”) of the EPO dated September 6, 2021, which dismissed the Company’s appeal of the previous Opposition Proceeding decision of the EPO Opposition Division to revoke the EP’355 patent, for reasons of procedural error made by the TBA.

On September 12, 2022, following the Company’s review of a preliminary opinion of the EBA regarding the Petition and consultation with the Company’s board of directors regarding the anticipated costs associated with continuation of the Petition proceedings and the Company’s cash resources, the Company submitted a request for a written decision regarding the Petition to the EBA. The Company expects to receive such written decision by the end of the year, which is expected to conclude the Opposition Proceeding.

~~For~~ ~~more~~ ~~information~~ ~~regarding~~Yes ~~the~~☐ ~~Opposition~~No ~~Proceeding, please see the Company’s Annual Report on Form 20-F for the year ended December 31, 2021.~~☒

~~SIGNATURE~~

~~Pursuant~~Indicate toby ~~the~~check ~~requirements~~mark ofif the ~~Securities~~registrant ~~Exchange Act~~is ofsubmitting ~~1934,~~ the ~~registrant~~Form ~~has~~6-K ~~duly~~in ~~caused~~paper ~~this~~as ~~report~~permitted ~~to be signed on its behalf~~ by ~~the~~Regulation ~~undersigned,~~S-T ~~thereunto~~Rule ~~duly authorized~~101(b)(7).

	FORWARD PHARMA A/S
Date: September 12, 2022	By:	/s/ Claus Bo Svendsen
		Name: Claus Bo Svendsen
		Title: Chief Executive Officer


	Yes ☐	No ☒

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.


	Yes ☐	No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

EXHIBIT INDEX


Exhibit No.	Description
99.1	Unaudited Interim Condensed Consolidated Financial Statements and Notes thereto

99.2	Management’s Discussion and Analysis of Financial Condition and Results of Operations

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


	Forward Pharma A/S

Date: November 9, 2022	By:	/s/ Claus Bo Svendsen
		Name: Claus Bo Svendsen
		Title: Chief Executive Officer

Filing Compare · Forward Pharma A/S